Praxis Medical Insights

Est. 2024 • Clinical Guidelines Distilled

Made possible by volunteer editors from the University of Calgary & University of Alberta

Last Updated: 9/26/2025

Aspirin for Atrial Fibrillation: Stroke Prevention

Evidence for Aspirin's Limited Efficacy

  • The American College of Cardiology recommends that aspirin should be reserved exclusively for patients at the lowest risk of stroke or those who absolutely cannot take oral anticoagulation, as it provides only modest stroke protection in atrial fibrillation 1, 2
  • A meta-analysis of 5 randomized trials demonstrated that aspirin reduces stroke risk by only 19% (95% CI: 2% to 34%) compared to placebo, with the confidence interval encompassing zero, meaning aspirin may have no real effect 1, 3, 4
  • The absolute risk reduction with aspirin is merely 0.8% per year for primary prevention, requiring treatment of 125 patients for one year to prevent a single stroke 2
  • Aspirin prevents primarily nondisabling strokes rather than disabling cardioembolic strokes, which are the most devastating type associated with atrial fibrillation 1, 3
  • The positive results from aspirin trials were driven almost entirely by a single study (SPAF-1), and even in that trial, aspirin was ineffective in patients over 75 years of age and did not prevent severe strokes 2

Oral Anticoagulation: The Superior Alternative

  • Warfarin reduces stroke risk by 64% (95% CI: 49% to 74%) compared to placebo, and provides a 33% risk reduction (95% CI: 13% to 49%) compared directly to aspirin 3, 4, 2
  • For high-risk patients, warfarin reduces absolute stroke risk by 2.7% per year, requiring treatment of only 37 patients for one year to prevent one stroke 2
  • Direct oral anticoagulants like apixaban are superior to aspirin with similar bleeding risk, as demonstrated in the AVERROES trial which was terminated early due to apixaban's clear superiority 2

Risk-Stratified Treatment Algorithm

  • For patients with NO risk factors, the American College of Cardiology recommends aspirin 81-325 mg daily as an acceptable option 1, 5
  • For patients with ONE moderate-risk factor, warfarin (INR 2.0-3.0) is preferred over aspirin 81-325 mg daily 1, 5
  • For patients with ANY high-risk factor or MORE THAN ONE moderate-risk factor, warfarin (INR 2.0-3.0, target 2.5) or a direct oral anticoagulant is mandatory, according to the American Academy of Family Physicians and the American College of Cardiology 6, 1, 5
  • High-risk factors include prior stroke/TIA, age ≥75 years, heart failure, hypertension, diabetes, as defined by the American Academy of Family Physicians and the American College of Cardiology 6, 1

Critical Pitfalls to Avoid

  • The American College of Cardiology advises against prescribing aspirin thinking it is "safer" than warfarin, as well-managed warfarin therapy (INR 2.0-3.0) has minimal effect on bleeding risk and is twice as effective as aspirin at preventing stroke 1, 3, 4
  • Combining aspirin with warfarin routinely is not recommended, as it increases intracranial hemorrhage risk, particularly in elderly patients, without providing additional stroke protection, according to the American College of Cardiology and the European Heart Journal 1, 3, 4
  • The European Heart Journal recommends against using low-intensity warfarin (INR <1.5) combined with aspirin, as this combination adds little protection against stroke compared to aspirin alone 3, 4
  • The American Academy of Family Physicians and the Stroke journal advise against prescribing aspirin for secondary prevention in atrial fibrillation, as vitamin K antagonists are recommended for patients with prior stroke or TIA, and aspirin alone is only for those unable to take oral anticoagulants 6, 7

REFERENCES